Premium
IC‐01‐05: Neuropathologic Features of AV1451 TAU Pet Autoradiography in Dementia
Author(s) -
Murray Melissa E.,
Curran Geoffry L.,
Fang Ping,
Josephs Keith A.,
Parisi Joseph E.,
Kantarci Kejal,
Boeve Bradley F.,
Pandey Mukesh,
Bruinsma Tyler J.,
Knopman David S.,
Jones David T.,
Petrucelli Leonard,
Cook Casey,
Dickson Dennis W.,
Petersen Ronald C.,
Jack Clifford R.,
Lowe Val J.
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.065
Subject(s) - substantia nigra , pathology , choroid plexus , senile plaques , tau pathology , dementia , gene isoform , alzheimer's disease , chemistry , medicine , neuroscience , parkinson's disease , biology , disease , central nervous system , biochemistry , gene
poral lobe atrophy and F -AV1451 PET imaging revealed uptake in the temporal and frontal lobes, as well as in the basal ganglia (Fig 1 C). The regional uptake of F -AV1451 correlated strongly with the tau aggregates revealed using immunohistochemistry (R 1⁄4 0.80, P < 0.01; Fig 2). All cases exhibited negative amyloid (F -flutemetamol) PET scans. Conclusions:The in vivo uptake of F-AV1451 reflects the regional amount of tau aggregates revealed by neuropathological examination. Further, tau pathology inMAPT mutation carriers is accurately detected with F -AV1451 PET, which consequently can be used to track the effects of anti-tau therapies in this patient group.